Clinical trial · Observational

Shanghai Lymphoma Clinical Cohort

NCT07285174CI-TRIAL-00099052not yet recruitingClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

The aim of this study is to prospectively collect clinical information on patients with lymphoma, and to explore the best therapeutic strategies in the real-world population.

Conditions

Conditions (2)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Cohort	—	UNRESOLVED	—
Lymphoma	Lymphoma	ONTOLOGY_EXACT	0.90

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
No interventions need to be specified for this study	Other	—	UNRESOLVED

Design

Arms and outcomes

Arms (1)

label
Shanghai Lymphoma Clinical Cohort
description
Shanghai Lymphoma Clinical Cohort
interventionNames
1. Other: No interventions need to be specified for this study

Primary outcomes (1)

measure
Progression Free Survival (PFS)
timeFrame
Baseline up to data cut-off (up to approximately 1 year)
description
Progression-Free Survival (PFS) will be defined from the date of starting therapy and the date of disease progression, relapse or death from any cause.

Secondary outcomes (1)

measure
Overall Survival (OS)
timeFrame
Baseline up to data cut-off (up to approximately 1 year)
description

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 16 Years

Show eligibility criteria text

Inclusion Criteria:

1. Age ≥ 16 years (including 16 years old).
2. Patients newly diagnosed with non-Hodgkin lymphoma
3. Patients who have received systematic clinical treatment.
4. Patients with measurable lesions, at least containing one effective evaluation of efficacy.

Exclusion Criteria:

1. Patients who only receive supportive treatment.
2. Patients who cannot obtain effective evaluation data of efficacy.

References

Publications (0)

Data not yet available

No reference posted for this study.